Collaboration agreement covers microRNA development and manufacturing

STA Pharmaceutical and Regulus Therapeutics have entered into a collaboration agreement covering oligonucleotide synthesis for research and mid-scale non-GMP/cGMP manufacturing.

STA becomes a strategic development and manufacturing partner for Regulus’s preclinical and clinical programmes of microRNA-targeting drugs.

Regulus will provide STA with expertise, technical know-how, and training in oligonucleotide scale-up.

STA has established oligonucleotide R&D labs at both its facilities in San Diego, California and Changzhou, China.

The oligonucleotide GMP manufacturing facility at Changzhou will become operational later in 2018.

Leave a Reply

Your email address will not be published. Required fields are marked *